Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. (NYSE American: SENS) filed a Form 8-K dated August 6, 2025 under Item 2.02 to furnish a press release (Exhibit 99.1) announcing its results for the quarter ended June 30, 2025. The press release also provides details for an accompanying conference call covering recent corporate highlights and the Company’s outlook. In accordance with SEC rules, the furnished material is not deemed “filed” for liability purposes and will not be incorporated by reference into other SEC filings. No quantitative financial data, guidance figures, or strategic updates are included in the 8-K itself.